Fig. 5From: De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysisROC curves at the 1-, 3-, and 5-year points in the training (A), internal validation (B), and external validation cohort (C). Calibration curves at the 1-, 3-, and 5-year points in the training (D), internal validation (E), and external validation cohort (F)Back to article page